SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
104,800
+800 (0.77%)
Apr 18, 2025, 3:30 PM KST

SK Biopharmaceuticals Revenue

In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B KRW with 54.30% growth. SK Biopharmaceuticals had revenue of 163.02B in the quarter ending December 31, 2024, with 28.61% growth.

Revenue
547.60B
Revenue Growth
+54.30%
P/S Ratio
14.99
Revenue / Employee
2.27B
Employees
241
Market Cap
8,207.23B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024547.60B192.70B54.30%
Dec 31, 2023354.89B108.71B44.16%
Dec 31, 2022246.18B-172.47B-41.20%
Dec 31, 2021418.64B392.65B1,510.23%
Dec 31, 202026.00B-97.85B-79.01%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,547.32B
Celltrion 3,557.30B
ALTEOGEN 102.85B
Yuhan 2,067.79B
HLB Co., Ltd. 68.13B
Peptron 3.15B
LigaChem Biosciences 125.90B
PharmaResearch 350.12B
Revenue Rankings